Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia
Ivana Gojo(Johns Hopkins University), Douglas D. Ross(Western University), Hong‐Bin Fang(University of Maryland, Baltimore), Jan H. Beumer(Johns Hopkins University), France Carrier(University of Maryland, Baltimore), Bean N. Anyang(University of Maryland, Baltimore), Mariola Sadowska(University of Maryland, Baltimore), Maria R. Baer(University of Maryland, Baltimore), Rena G. Lapidus(University of Maryland, Baltimore), Ming Tan(University of Maryland, Baltimore), Igor Espinoza‐Delgado(National Institutes of Health)
Cited by 49
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764